Swedish Orphan Biovitrum makes payment to vendors of Cambridge Biotechnology Limited

Swedish Orphan Biovitrum entered into a share purchase agreement in connection
with the acquisition of Cambridge Biotechnology Limited (CBT) in April 2005. In
accordance with this agreement the vendors of CBT are entitled to deferred
payments as a result of Swedish Orphan Biovitrum's sale of its leptin modulator
program to AstraZeneca. Deferred payments have been made by cash payment and by
conversion of previously issued convertibles into  a total of 2,373,300 common
shares in Swedish Orphan Biovitrum.

The conversion has been effected today by registration with the Swedish
Companies Registration Office, where after the total number of shares in the
company amounts to 212,414,439, whereof 211,898,854 common shares and 515,585
class C shares[1], and the share capital amounts to SEK 116,551,136.


For further information, please contact:
Erik Kinnman, EVP Investor Relations Biovitrum
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com <mailto:erik.kinnman@biovitrum.com>


About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipeline within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com <http://www.biovitrum.com/>.




Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on April 6, 2010 at 14:00 p.m. CET.



--------------------------------------------------------------------------------

[1] All class C shares are held by Swedish Orphan Biovitrum.



[HUG#1400780]